Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold

Overexpression of both human murine double minute 2 (MDM2) and X-linked inhibitor of Apoptosis protein (XIAP) is detected in tumor cells from several Cancer types, including childhood acute leukemia lymphoma (ALL), neuroblastoma (NB), and prostate Cancer, and is associated with disease progression and treatment resistance. In this report, we described the design and syntheses of a series of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold from our previously reported lead compound JW-2-107 and tested their cytotoxicity in a panel of human Cancer cell lines. The best compound identified in this study is compound 3e. Western blot analyses demonstrated that treatments with 3e decreased MDM2 and XIAP protein levels and increased expression of p53, resulting in Cancer cell growth inhibition and cell death. Furthermore, compound 3e effectively inhibited tumor growth in vivo when tested using a human 22Rv1 prostate Cancer xenograft model. Collectively, results in this study strongly suggest that the tetrahydroquinoline scaffold, represented by 3e and our earlier lead compound JW-2-107, has abilities to dual target MDM2 and XIAP and is promising for further preclinical development.

Antiproliferative activities; Dual MDM2/XIAP inhibitors; Human 22Rv1 prostate xenograft model; MDM2; Structure-activity relationships; XIAP.